Morgan Stanley Reaffirms Buy Rating for Vir Biotechnology, Inc.

Morgan Stanley has reiterated its buy rating on Vir Biotechnology, Inc. (NasdaqGS: VIR), setting a price target of $27. The announcement came from analyst Michelle Gilson on June 11, 2026. This rating suggests continued confidence in the company's future prospects.

Other Institutional Activity in Vir Biotechnology

Several major funds have been active with Vir Biotechnology, Inc. BlackRock, Inc. increased its holdings by 1,668,226 shares, bringing its total to 17,998,329 shares valued at about $161.27 million. Arch Venture Management, LLC maintained its position at 12,916,663 shares worth $115.73 million. SB Investment Advisers (UK) Ltd reduced its stake by 2,168,884 shares, ending with 10,948,093 shares valued at $98.09 million. Vanguard Portfolio Management LLC added 9,215,577 shares, reaching the same count, valued at $82.57 million. State Street Corp also grew its position by 911,539 shares to 7,141,094 shares, valued at $63.98 million.

Vir Biotechnology, Inc. Stock Snapshot

Shares of Vir Biotechnology, Inc. are currently trading around $8.51. The company has a market cap of approximately $1.45 billion. It operates with a forward P/E ratio of -3.71, indicating it is not currently profitable. The stock has shown volatility with a 52-week low of $4.16 and a high of $11.66. Its 50-day moving average is $9.50, and the 200-day moving average is $7.38. Vir maintains a strong liquidity position with a current ratio of 7.11 and a quick ratio of 6.52, while its debt-to-equity ratio stands at 11.76.

Recent Earnings

In its recent earnings report, Vir Biotechnology posted revenue of $65.5 million. Despite a net margin of 0%, the company is focusing on growth in its biotechnology pipeline. The return on equity stands at -47.7%, reflecting the challenges in achieving profitability. The next earnings report is expected on May 6, 2026.

Insider Buying and Selling at Vir Biotechnology, Inc.

Recent insider activity at Vir Biotechnology includes multiple share purchases. Timothy Coughlin bought 16,000 shares on June 9, 2026. On the same day, Janet Napolitano and Brent Sabatini sold 3,200 and 379 shares, respectively, at $9.45 per share as part of a planned sale. Ramy Farid and Robert More also acquired 8,000 and 16,000 shares, respectively, in late May.

Analysts Set New Price Targets

On June 11, 2026, Morgan Stanley maintained its buy rating on Vir Biotechnology with a $27 price target. Other analysts, such as Leerink Partners and HC Wainwright & Co., have also maintained buy ratings with targets of $21 and $20, respectively. The consensus among nine analysts is a strong buy, with a mean target price of $21.56.

About Vir Biotechnology, Inc.

Vir Biotechnology, Inc. is a clinical-stage biopharmaceutical company headquartered in San Francisco, California. It focuses on discovering and developing therapeutic products to treat and prevent serious infectious diseases. The company is working on investigational therapies targeting hepatitis delta virus (HDV) and various solid tumors. It has partnerships and agreements with several organizations, including Astellas and the Gates Foundation, to advance its research and development efforts. Led by CEO Dr. Marianne De Backer, Vir employs around 367 people.

Bottom Line

Morgan Stanley's reaffirmation of a buy rating for Vir Biotechnology, Inc. underscores the bank's confidence in the company's potential. While the stock is currently trading below the $10 mark, the reiterated $27 price target reflects optimism about its future. Investors keep a close eye on such analyst ratings and institutional activities as indicators of a company's prospects. Remember, 13F filings and analyst ratings are backward-looking and should be considered as part of a broader investment strategy.